Condition: Breast Cancer Stage IV · Triple -Negative Breast Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.
This description comes directly from the study's public registry record.
Jieqiong Liu, M.D., Ph.D. · +86-020-34071156 · liujieqiong01@163.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| Wuhan Union Hospital of China | Wuhan, Hubei, China | Not Yet Recruiting |
| Yichang Central People's Hospital | Yichang, Hubei, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| The Central Hospital Of Yong Zhou | Yongzhou, Hunan, China | Recruiting |
| Changhai Hospital of Shanghai | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06889688